The distributor of Zomig Tab, a triptan used in the treatment of migraine, will change from AstraZeneca Korea to SK Chemical. The distribution industry suggests that the change in a distributor could impact the supply and demand chain.

AstraZeneca Korea recently sent an official letter to the pharmaceutical wholesaler community of 'termination of a distribution agreement and changes to distributor' of Zomig Tab.

The company stated in the official letter that starting on October 1st, due to the sales agreement, Zomig Tab 2.5 mg distributor will change from AstraZeneca Korea to SK Chemicals.

Zomig Tab has been in shortage several times. The Ministry of Food and Drug Safety (